<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Beta Footprint</title>
	<atom:link href="http://www.betafootprint.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.betafootprint.com</link>
	<description>Carbon footprint reduction guide</description>
	<lastBuildDate>Fri, 11 Dec 2009 10:20:44 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Asymmetric endoscopic inflammation of the ileal pouch: A sign of ischemic pouchitis?</title>
		<link>http://www.betafootprint.com/medical-news/asymmetric-endoscopic-inflammation-of-the-ileal-pouch-a-sign-of-ischemic-pouchitis/</link>
		<comments>http://www.betafootprint.com/medical-news/asymmetric-endoscopic-inflammation-of-the-ileal-pouch-a-sign-of-ischemic-pouchitis/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:44 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[inflamm-bowel]]></category>
		<category><![CDATA[may-represent]]></category>
		<category><![CDATA[pouch]]></category>
		<category><![CDATA[pouchitis-did]]></category>
		<category><![CDATA[pouchitis-were]]></category>
		<category><![CDATA[staple-suture]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[the-pouch]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/asymmetric-endoscopic-inflammation-of-the-ileal-pouch-a-sign-of-ischemic-pouchitis/</guid>
		<description><![CDATA[ Inflamm Bowel Dis . 2009 Dec 8; Shen B, Plesec TP, Remer E, Kiran P, Remzi FH, Lopez R, Fazio VW, Goldblum JR BACKGROUND:: Pouchitis is associated with dysbiosis and dysregulated mucosal immunity, although secondary pouchitis with special etiologic factors, such as ischemia, can occur. The aim was to describe a disease phenotype of the ileal pouch with an endoscopic appearance suggestive of ischemia]]></description>
			<content:encoded><![CDATA[<p> Inflamm Bowel Dis . 2009 Dec 8; Shen B, Plesec TP, Remer E, Kiran P, Remzi FH, Lopez R, Fazio VW, Goldblum JR BACKGROUND:: Pouchitis is associated with dysbiosis and dysregulated mucosal immunity, although secondary pouchitis with special etiologic factors, such as ischemia, can occur. The aim was to describe a disease phenotype of the ileal pouch with an endoscopic appearance suggestive of ischemia</p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/asymmetric-endoscopic-inflammation-of-the-ileal-pouch-a-sign-of-ischemic-pouchitis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pseudometastasis secondary to histoplasmosis infection: False-positive PET/CT findings.</title>
		<link>http://www.betafootprint.com/medical-news/pseudometastasis-secondary-to-histoplasmosis-infection-false-positive-petct-findings/</link>
		<comments>http://www.betafootprint.com/medical-news/pseudometastasis-secondary-to-histoplasmosis-infection-false-positive-petct-findings/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:43 +0000</pubDate>
		<dc:creator>Master</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[biopsy-results]]></category>
		<category><![CDATA[blood]]></category>
		<category><![CDATA[common-modality]]></category>
		<category><![CDATA[complete-course]]></category>
		<category><![CDATA[diagnoses]]></category>
		<category><![CDATA[messinger]]></category>
		<category><![CDATA[one-patient]]></category>
		<category><![CDATA[patients-were]]></category>
		<category><![CDATA[pediatr-blood]]></category>
		<category><![CDATA[results-may]]></category>
		<category><![CDATA[the-diagnoses]]></category>
		<category><![CDATA[workup]]></category>
		<category><![CDATA[young-adult]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/pseudometastasis-secondary-to-histoplasmosis-infection-false-positive-petct-findings/</guid>
		<description><![CDATA[ Pediatr Blood Cancer . 2009 Dec 8; Perko R, Messinger Y, Moertel C Positron emission computed tomography (PET)/CT is a common modality used in the workup of neoplastic conditions. ]]></description>
			<content:encoded><![CDATA[<p> Pediatr Blood Cancer . 2009 Dec 8; Perko R, Messinger Y, Moertel C Positron emission computed tomography (PET)/CT is a common modality used in the workup of neoplastic conditions. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/pseudometastasis-secondary-to-histoplasmosis-infection-false-positive-petct-findings/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Successful mobilization, harvest and transplant of peripheral blood stem cells using AMD3100 and G-CSF following high dose craniospinal irradiation&#8230;</title>
		<link>http://www.betafootprint.com/medical-news/successful-mobilization-harvest-and-transplant-of-peripheral-blood-stem-cells-using-amd3100-and-g-csf-following-high-dose-craniospinal-irradiation/</link>
		<comments>http://www.betafootprint.com/medical-news/successful-mobilization-harvest-and-transplant-of-peripheral-blood-stem-cells-using-amd3100-and-g-csf-following-high-dose-craniospinal-irradiation/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[after-recent]]></category>
		<category><![CDATA[blood]]></category>
		<category><![CDATA[cxcr4]]></category>
		<category><![CDATA[malignant-brain]]></category>
		<category><![CDATA[often-require]]></category>
		<category><![CDATA[serial-courses]]></category>
		<category><![CDATA[successful]]></category>
		<category><![CDATA[the-treatment]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[type]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/successful-mobilization-harvest-and-transplant-of-peripheral-blood-stem-cells-using-amd3100-and-g-csf-following-high-dose-craniospinal-irradiation/</guid>
		<description><![CDATA[ Pediatr Blood Cancer . 2009 Dec 8; Toledano H, Yahel A, Cohen IJ, Yaniv I, Stein J Contemporary protocols for the treatment of malignant brain tumors such as medulloblastoma (MB) in children, often involve craniospinal irradiation (CSI) at diagnosis followed by serial courses of high dose chemotherapy and autologous hematopoietic stem cell support. ]]></description>
			<content:encoded><![CDATA[<p> Pediatr Blood Cancer . 2009 Dec 8; Toledano H, Yahel A, Cohen IJ, Yaniv I, Stein J Contemporary protocols for the treatment of malignant brain tumors such as medulloblastoma (MB) in children, often involve craniospinal irradiation (CSI) at diagnosis followed by serial courses of high dose chemotherapy and autologous hematopoietic stem cell support. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/successful-mobilization-harvest-and-transplant-of-peripheral-blood-stem-cells-using-amd3100-and-g-csf-following-high-dose-craniospinal-irradiation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous&#8230;</title>
		<link>http://www.betafootprint.com/medical-news/thiotepatopotecancarboplatin-with-autologous-stem-cell-rescue-in-recurrentrefractorypoor-prognosis-pediatric-malignancies-of-the-central-nervous/</link>
		<comments>http://www.betafootprint.com/medical-news/thiotepatopotecancarboplatin-with-autologous-stem-cell-rescue-in-recurrentrefractorypoor-prognosis-pediatric-malignancies-of-the-central-nervous/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:42 +0000</pubDate>
		<dc:creator>Master</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[after-treatment]]></category>
		<category><![CDATA[blood]]></category>
		<category><![CDATA[central-nervous]]></category>
		<category><![CDATA[disease-status]]></category>
		<category><![CDATA[nervous-system]]></category>
		<category><![CDATA[patients]]></category>
		<category><![CDATA[pediatr-blood]]></category>
		<category><![CDATA[poor-prognosis]]></category>
		<category><![CDATA[thiotepa]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[under-the-curve]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/thiotepatopotecancarboplatin-with-autologous-stem-cell-rescue-in-recurrentrefractorypoor-prognosis-pediatric-malignancies-of-the-central-nervous/</guid>
		<description><![CDATA[ Pediatr Blood Cancer . 2009 Dec 8; Gilheeney SW, Khakoo Y, Souweidane M, Wolden S, Boulad F, Dunkel IJ BACKGROUND: Thiotepa and carboplatin are known to be active in central nervous system tumors. Topotecan potentiates the anti-cancer effects of alkylators and crosses the blood-brain barrier]]></description>
			<content:encoded><![CDATA[<p> Pediatr Blood Cancer . 2009 Dec 8; Gilheeney SW, Khakoo Y, Souweidane M, Wolden S, Boulad F, Dunkel IJ BACKGROUND: Thiotepa and carboplatin are known to be active in central nervous system tumors. Topotecan potentiates the anti-cancer effects of alkylators and crosses the blood-brain barrier</p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/thiotepatopotecancarboplatin-with-autologous-stem-cell-rescue-in-recurrentrefractorypoor-prognosis-pediatric-malignancies-of-the-central-nervous/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pancreatic tumors in children and adolescents: The Italian TREP project experience.</title>
		<link>http://www.betafootprint.com/medical-news/pancreatic-tumors-in-children-and-adolescents-the-italian-trep-project-experience/</link>
		<comments>http://www.betafootprint.com/medical-news/pancreatic-tumors-in-children-and-adolescents-the-italian-trep-project-experience/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:42 +0000</pubDate>
		<dc:creator>Master</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[complete-tumor]]></category>
		<category><![CDATA[distant-relapse]]></category>
		<category><![CDATA[endocrine]]></category>
		<category><![CDATA[first-remission]]></category>
		<category><![CDATA[italian]]></category>
		<category><![CDATA[pediatr-blood]]></category>
		<category><![CDATA[pediatric-age]]></category>
		<category><![CDATA[surgery]]></category>
		<category><![CDATA[tumor-resection]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/pancreatic-tumors-in-children-and-adolescents-the-italian-trep-project-experience/</guid>
		<description><![CDATA[ Pediatr Blood Cancer . 2009 Dec 8; Dall'igna P, Cecchetto G, Bisogno G, Conte M, Chiesa PL, D'Angelo P, De Leonardis F, De Salvo G, Favini F, Ferrari A, INTRODUCTION: Malignant pancreatic tumors are exceedingly rare in pediatric age and their clinical features and treatment usually go unappreciated by most pediatric oncologists and surgeons]]></description>
			<content:encoded><![CDATA[<p> Pediatr Blood Cancer . 2009 Dec 8; Dall&#8217;igna P, Cecchetto G, Bisogno G, Conte M, Chiesa PL, D&#8217;Angelo P, De Leonardis F, De Salvo G, Favini F, Ferrari A, INTRODUCTION: Malignant pancreatic tumors are exceedingly rare in pediatric age and their clinical features and treatment usually go unappreciated by most pediatric oncologists and surgeons</p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/pancreatic-tumors-in-children-and-adolescents-the-italian-trep-project-experience/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in&#8230;</title>
		<link>http://www.betafootprint.com/medical-news/polyadp-ribosepolymerase-inhibitor-can-attenuate-the-neuronal-death-after-1-methyl-4-phenyl-1236-tetrahydropyridine-induced-neurotoxicity-in/</link>
		<comments>http://www.betafootprint.com/medical-news/polyadp-ribosepolymerase-inhibitor-can-attenuate-the-neuronal-death-after-1-methyl-4-phenyl-1236-tetrahydropyridine-induced-neurotoxicity-in/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:41 +0000</pubDate>
		<dc:creator>Master</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[hplc]]></category>
		<category><![CDATA[mptp]]></category>
		<category><![CDATA[neurosci]]></category>
		<category><![CDATA[parkinson]]></category>
		<category><![CDATA[parp]]></category>
		<category><![CDATA[study-showed]]></category>
		<category><![CDATA[the-therapeutic]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[time-window]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/polyadp-ribosepolymerase-inhibitor-can-attenuate-the-neuronal-death-after-1-methyl-4-phenyl-1236-tetrahydropyridine-induced-neurotoxicity-in/</guid>
		<description><![CDATA[ J Neurosci Res . 2009 Dec 8; Yokoyama H, Kuroiwa H, Tsukada T, Uchida H, Kato H, Araki T An excessive expression of poly(ADP-ribose)polymerase (PARP) has been demonstrated to play a key role in the pathogenesis of Parkinson's disease (PD). ]]></description>
			<content:encoded><![CDATA[<p> J Neurosci Res . 2009 Dec 8; Yokoyama H, Kuroiwa H, Tsukada T, Uchida H, Kato H, Araki T An excessive expression of poly(ADP-ribose)polymerase (PARP) has been demonstrated to play a key role in the pathogenesis of Parkinson&#8217;s disease (PD). </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/polyadp-ribosepolymerase-inhibitor-can-attenuate-the-neuronal-death-after-1-methyl-4-phenyl-1236-tetrahydropyridine-induced-neurotoxicity-in/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Functional silica nanoparticle-mediated neuronal membrane sealing following traumatic spinal cord injury.</title>
		<link>http://www.betafootprint.com/medical-news/functional-silica-nanoparticle-mediated-neuronal-membrane-sealing-following-traumatic-spinal-cord-injury/</link>
		<comments>http://www.betafootprint.com/medical-news/functional-silica-nanoparticle-mediated-neuronal-membrane-sealing-following-traumatic-spinal-cord-injury/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:40 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[concentration]]></category>
		<category><![CDATA[contusion-model]]></category>
		<category><![CDATA[derangement]]></category>
		<category><![CDATA[formation]]></category>
		<category><![CDATA[hydrophilic]]></category>
		<category><![CDATA[novel-treatment]]></category>
		<category><![CDATA[particles]]></category>
		<category><![CDATA[processes]]></category>
		<category><![CDATA[their-processes]]></category>
		<category><![CDATA[traumatic-brain]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/functional-silica-nanoparticle-mediated-neuronal-membrane-sealing-following-traumatic-spinal-cord-injury/</guid>
		<description><![CDATA[ J Neurosci Res . 2009 Dec 8; Cho Y, Shi R, Ivanisevic A, Ben Borgens R The mechanical damage to neurons and their processes induced by spinal cord injury (SCI) causes a progressive cascade of pathophysiological events beginning with the derangement of ionic equilibrium and collapse of membrane permeability]]></description>
			<content:encoded><![CDATA[<p> J Neurosci Res . 2009 Dec 8; Cho Y, Shi R, Ivanisevic A, Ben Borgens R The mechanical damage to neurons and their processes induced by spinal cord injury (SCI) causes a progressive cascade of pathophysiological events beginning with the derangement of ionic equilibrium and collapse of membrane permeability</p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/functional-silica-nanoparticle-mediated-neuronal-membrane-sealing-following-traumatic-spinal-cord-injury/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sulforaphane protects immature hippocampal neurons against death caused by exposure to hemin or to oxygen and glucose deprivation.</title>
		<link>http://www.betafootprint.com/medical-news/sulforaphane-protects-immature-hippocampal-neurons-against-death-caused-by-exposure-to-hemin-or-to-oxygen-and-glucose-deprivation/</link>
		<comments>http://www.betafootprint.com/medical-news/sulforaphane-protects-immature-hippocampal-neurons-against-death-caused-by-exposure-to-hemin-or-to-oxygen-and-glucose-deprivation/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:39 +0000</pubDate>
		<dc:creator>Master</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[after-the-ogd]]></category>
		<category><![CDATA[against-injury]]></category>
		<category><![CDATA[control-neurons]]></category>
		<category><![CDATA[hypothesis]]></category>
		<category><![CDATA[nrf2-dependent]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[the-antioxidant]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/sulforaphane-protects-immature-hippocampal-neurons-against-death-caused-by-exposure-to-hemin-or-to-oxygen-and-glucose-deprivation/</guid>
		<description><![CDATA[ J Neurosci Res . 2009 Dec 8; Soane L, Li Dai W, Fiskum G, Bambrick LL Oxidative stress is a mediator of cell death following cerebral ischemia/reperfusion and heme toxicity, which can be an important pathogenic factor in acute brain injury. ]]></description>
			<content:encoded><![CDATA[<p> J Neurosci Res . 2009 Dec 8; Soane L, Li Dai W, Fiskum G, Bambrick LL Oxidative stress is a mediator of cell death following cerebral ischemia/reperfusion and heme toxicity, which can be an important pathogenic factor in acute brain injury. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/sulforaphane-protects-immature-hippocampal-neurons-against-death-caused-by-exposure-to-hemin-or-to-oxygen-and-glucose-deprivation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Human umbilical cord blood cell therapy blocks the morphological change and recruitment of CD11b-expressing, isolectin-binding proinflammatory cells&#8230;</title>
		<link>http://www.betafootprint.com/medical-news/human-umbilical-cord-blood-cell-therapy-blocks-the-morphological-change-and-recruitment-of-cd11b-expressing-isolectin-binding-proinflammatory-cells/</link>
		<comments>http://www.betafootprint.com/medical-news/human-umbilical-cord-blood-cell-therapy-blocks-the-morphological-change-and-recruitment-of-cd11b-expressing-isolectin-binding-proinflammatory-cells/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:38 +0000</pubDate>
		<dc:creator>Master</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[cell-treatment]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[greater-numbers]]></category>
		<category><![CDATA[middle-cerebral]]></category>
		<category><![CDATA[migration]]></category>
		<category><![CDATA[morphology]]></category>
		<category><![CDATA[protective]]></category>
		<category><![CDATA[surface-markers]]></category>
		<category><![CDATA[the-morphology]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/human-umbilical-cord-blood-cell-therapy-blocks-the-morphological-change-and-recruitment-of-cd11b-expressing-isolectin-binding-proinflammatory-cells/</guid>
		<description><![CDATA[ J Neurosci Res . 2009 Dec 8; Leonardo CC, Hall AA, Collier LA, Ajmo CT, Willing AE, Pennypacker KR Secondary neurodegeneration resulting from stroke is mediated by delayed proinflammatory signaling and immune cell activation. Although it remains unknown which cell surface markers signify a proinflammatory phenotype, increased isolectin binding occurs on CD11b-expressing immune cells within injured brain tissue]]></description>
			<content:encoded><![CDATA[<p> J Neurosci Res . 2009 Dec 8; Leonardo CC, Hall AA, Collier LA, Ajmo CT, Willing AE, Pennypacker KR Secondary neurodegeneration resulting from stroke is mediated by delayed proinflammatory signaling and immune cell activation. Although it remains unknown which cell surface markers signify a proinflammatory phenotype, increased isolectin binding occurs on CD11b-expressing immune cells within injured brain tissue</p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/human-umbilical-cord-blood-cell-therapy-blocks-the-morphological-change-and-recruitment-of-cd11b-expressing-isolectin-binding-proinflammatory-cells/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Enhanced neurogenesis in the olfactory bulb in adult mice after injury induced by acute treatment with trimethyltin.</title>
		<link>http://www.betafootprint.com/medical-news/enhanced-neurogenesis-in-the-olfactory-bulb-in-adult-mice-after-injury-induced-by-acute-treatment-with-trimethyltin/</link>
		<comments>http://www.betafootprint.com/medical-news/enhanced-neurogenesis-in-the-olfactory-bulb-in-adult-mice-after-injury-induced-by-acute-treatment-with-trimethyltin/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:38 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[acute-treatment]]></category>
		<category><![CDATA[assay-revealed]]></category>
		<category><![CDATA[causes-neuronal]]></category>
		<category><![CDATA[cell-layer]]></category>
		<category><![CDATA[cells-on-day]]></category>
		<category><![CDATA[current]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[granular]]></category>
		<category><![CDATA[neuronal-cells]]></category>
		<category><![CDATA[subventricular]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/enhanced-neurogenesis-in-the-olfactory-bulb-in-adult-mice-after-injury-induced-by-acute-treatment-with-trimethyltin/</guid>
		<description><![CDATA[ J Neurosci Res . 2009 Dec 8; Yoneyama M, Kawada K, Ogita K In adults, the subventricular zone is known to contain undifferentiated neural progenitor cells that proliferate and generate the olfactory bulb (OB) interneurons throughout life. We earlier showed that trimethyltin (TMT) causes neuronal damage in the granular cell layer of the OB in adult mice]]></description>
			<content:encoded><![CDATA[<p> J Neurosci Res . 2009 Dec 8; Yoneyama M, Kawada K, Ogita K In adults, the subventricular zone is known to contain undifferentiated neural progenitor cells that proliferate and generate the olfactory bulb (OB) interneurons throughout life. We earlier showed that trimethyltin (TMT) causes neuronal damage in the granular cell layer of the OB in adult mice</p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/enhanced-neurogenesis-in-the-olfactory-bulb-in-adult-mice-after-injury-induced-by-acute-treatment-with-trimethyltin/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinical relevance and public health significance of hepatitis B virus genomic variations.</title>
		<link>http://www.betafootprint.com/medical-news/clinical-relevance-and-public-health-significance-of-hepatitis-b-virus-genomic-variations/</link>
		<comments>http://www.betafootprint.com/medical-news/clinical-relevance-and-public-health-significance-of-hepatitis-b-virus-genomic-variations/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:37 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[acute-hepatitis]]></category>
		<category><![CDATA[acute-infection]]></category>
		<category><![CDATA[gastroenterol]]></category>
		<category><![CDATA[hbv]]></category>
		<category><![CDATA[increased-risk]]></category>
		<category><![CDATA[polymerase-gene]]></category>
		<category><![CDATA[pres]]></category>
		<category><![CDATA[selected-during]]></category>
		<category><![CDATA[via-horizontal]]></category>
		<category><![CDATA[worse-outcome]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/clinical-relevance-and-public-health-significance-of-hepatitis-b-virus-genomic-variations/</guid>
		<description><![CDATA[ World J Gastroenterol . ]]></description>
			<content:encoded><![CDATA[<p> World J Gastroenterol . </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/clinical-relevance-and-public-health-significance-of-hepatitis-b-virus-genomic-variations/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NT4(Si)-p53(N15)-antennapedia induces cell death in a human hepatocellular carcinoma cell line.</title>
		<link>http://www.betafootprint.com/medical-news/nt4si-p53n15-antennapedia-induces-cell-death-in-a-human-hepatocellular-carcinoma-cell-line/</link>
		<comments>http://www.betafootprint.com/medical-news/nt4si-p53n15-antennapedia-induces-cell-death-in-a-human-hepatocellular-carcinoma-cell-line/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:36 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[analysis-showed]]></category>
		<category><![CDATA[being-the-main]]></category>
		<category><![CDATA[being-the-minor]]></category>
		<category><![CDATA[cells-infected]]></category>
		<category><![CDATA[difference]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[inhibited-tumor]]></category>
		<category><![CDATA[inhibition-rate]]></category>
		<category><![CDATA[inhibitory]]></category>
		<category><![CDATA[longer-the-time]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[treatment-group]]></category>
		<category><![CDATA[vitro-on-hepg2]]></category>
		<category><![CDATA[vivo-experiment]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/nt4si-p53n15-antennapedia-induces-cell-death-in-a-human-hepatocellular-carcinoma-cell-line/</guid>
		<description><![CDATA[ World J Gastroenterol . 2009 Dec 14; 15(46): 5813-20 Song LP, Li YP, Wang N, Li WW, Ren J, Qiu SD, Wang QY, Yang GX AIM: To construct the recombinant lentivirus expression plasmid, pLenti6/V5-NT4 p53(N15)-antennapedia (Ant), and study its effect on HepG2 cells. METHODS: Plasmid pLenti6/V5-NT4 p53(N15)-Ant was constructed incorporating the following functional regions, including signal peptide sequence and pro-region of neurotrophin 4, N-terminal residues 12-26 of p53 and 17 amino acid drosophila carrier protein, Ant. ]]></description>
			<content:encoded><![CDATA[<p> World J Gastroenterol . 2009 Dec 14; 15(46): 5813-20 Song LP, Li YP, Wang N, Li WW, Ren J, Qiu SD, Wang QY, Yang GX AIM: To construct the recombinant lentivirus expression plasmid, pLenti6/V5-NT4 p53(N15)-antennapedia (Ant), and study its effect on HepG2 cells. METHODS: Plasmid pLenti6/V5-NT4 p53(N15)-Ant was constructed incorporating the following functional regions, including signal peptide sequence and pro-region of neurotrophin 4, N-terminal residues 12-26 of p53 and 17 amino acid drosophila carrier protein, Ant. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/nt4si-p53n15-antennapedia-induces-cell-death-in-a-human-hepatocellular-carcinoma-cell-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Image-guided conservative management of right colonic diverticulitis.</title>
		<link>http://www.betafootprint.com/medical-news/image-guided-conservative-management-of-right-colonic-diverticulitis/</link>
		<comments>http://www.betafootprint.com/medical-news/image-guided-conservative-management-of-right-colonic-diverticulitis/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:36 +0000</pubDate>
		<dc:creator>Master</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[139-patients]]></category>
		<category><![CDATA[183-patients]]></category>
		<category><![CDATA[189-patients]]></category>
		<category><![CDATA[bowel-rest]]></category>
		<category><![CDATA[clinical]]></category>
		<category><![CDATA[eighty-three]]></category>
		<category><![CDATA[gastroenterol]]></category>
		<category><![CDATA[right-colonic]]></category>
		<category><![CDATA[second-attack]]></category>
		<category><![CDATA[stages]]></category>
		<category><![CDATA[the-stages]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/image-guided-conservative-management-of-right-colonic-diverticulitis/</guid>
		<description><![CDATA[ World J Gastroenterol . 2009 Dec 14; 15(46): 5838-42 Park SJ, Choi SI, Lee SH, Lee KY AIM: To study the clinical outcomes of medical therapy in patients with right colonic diverticulitis. METHODS: The records of 189 patients with right colonic diverticulitis which was finally diagnosed by computed tomography, ultrasonography, or operative findings were retrospectively reviewed]]></description>
			<content:encoded><![CDATA[<p> World J Gastroenterol . 2009 Dec 14; 15(46): 5838-42 Park SJ, Choi SI, Lee SH, Lee KY AIM: To study the clinical outcomes of medical therapy in patients with right colonic diverticulitis. METHODS: The records of 189 patients with right colonic diverticulitis which was finally diagnosed by computed tomography, ultrasonography, or operative findings were retrospectively reviewed</p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/image-guided-conservative-management-of-right-colonic-diverticulitis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.</title>
		<link>http://www.betafootprint.com/medical-news/neoadjuvant-peptide-receptor-radionuclide-therapy-for-an-inoperable-neuroendocrine-pancreatic-tumor/</link>
		<comments>http://www.betafootprint.com/medical-news/neoadjuvant-peptide-receptor-radionuclide-therapy-for-an-inoperable-neuroendocrine-pancreatic-tumor/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:35 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[abdomen]]></category>
		<category><![CDATA[among-the-most]]></category>
		<category><![CDATA[endocrine-tumor]]></category>
		<category><![CDATA[gastroenterol]]></category>
		<category><![CDATA[its-subsequent]]></category>
		<category><![CDATA[most-common]]></category>
		<category><![CDATA[resulted]]></category>
		<category><![CDATA[the-first]]></category>
		<category><![CDATA[the-tumor]]></category>
		<category><![CDATA[tumor]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/neoadjuvant-peptide-receptor-radionuclide-therapy-for-an-inoperable-neuroendocrine-pancreatic-tumor/</guid>
		<description><![CDATA[ World J Gastroenterol . 2009 Dec 14; 15(46): 5867-70 Kaemmerer D, Prasad V, Daffner W, Hörsch D, Klöppel G, Hommann M, Baum RP Pancreatic endocrine tumors are rare but are among the most common neuroendocrine neoplasms of the abdomen. ]]></description>
			<content:encoded><![CDATA[<p> World J Gastroenterol . 2009 Dec 14; 15(46): 5867-70 Kaemmerer D, Prasad V, Daffner W, Hörsch D, Klöppel G, Hommann M, Baum RP Pancreatic endocrine tumors are rare but are among the most common neuroendocrine neoplasms of the abdomen. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/neoadjuvant-peptide-receptor-radionuclide-therapy-for-an-inoperable-neuroendocrine-pancreatic-tumor/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Spontaneous liver rupture in hypereosinophilic syndrome: A rare but fatal complication.</title>
		<link>http://www.betafootprint.com/medical-news/spontaneous-liver-rupture-in-hypereosinophilic-syndrome-a-rare-but-fatal-complication/</link>
		<comments>http://www.betafootprint.com/medical-news/spontaneous-liver-rupture-in-hypereosinophilic-syndrome-a-rare-but-fatal-complication/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[case-report]]></category>
		<category><![CDATA[diagnosis]]></category>
		<category><![CDATA[gastroenterol]]></category>
		<category><![CDATA[knowledge]]></category>
		<category><![CDATA[liver-rupture]]></category>
		<category><![CDATA[management-were]]></category>
		<category><![CDATA[our-knowledge]]></category>
		<category><![CDATA[possible-cause]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/spontaneous-liver-rupture-in-hypereosinophilic-syndrome-a-rare-but-fatal-complication/</guid>
		<description><![CDATA[ World J Gastroenterol . 2009 Dec 14; 15(46): 5875-8 Cheung YS, Wong S, Lam PK, Lee KF, Wong J, Lai PB We report a rare case of spontaneous liver rupture in a patient with hypereosinophilic syndrome (HES), of which the diagnosis was delayed, resulting in a fatal outcome. ]]></description>
			<content:encoded><![CDATA[<p> World J Gastroenterol . 2009 Dec 14; 15(46): 5875-8 Cheung YS, Wong S, Lam PK, Lee KF, Wong J, Lai PB We report a rare case of spontaneous liver rupture in a patient with hypereosinophilic syndrome (HES), of which the diagnosis was delayed, resulting in a fatal outcome. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/spontaneous-liver-rupture-in-hypereosinophilic-syndrome-a-rare-but-fatal-complication/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Surgery for rare aneurysm associated with colorectal cancer.</title>
		<link>http://www.betafootprint.com/medical-news/surgery-for-rare-aneurysm-associated-with-colorectal-cancer/</link>
		<comments>http://www.betafootprint.com/medical-news/surgery-for-rare-aneurysm-associated-with-colorectal-cancer/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[aneurysm]]></category>
		<category><![CDATA[aortic-aneurysm]]></category>
		<category><![CDATA[ascending]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[gastroenterol]]></category>
		<category><![CDATA[patient]]></category>
		<category><![CDATA[specimen-showed]]></category>
		<category><![CDATA[surgical]]></category>
		<category><![CDATA[surrounds-its]]></category>
		<category><![CDATA[the-ascending]]></category>
		<category><![CDATA[the-surgical]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/surgery-for-rare-aneurysm-associated-with-colorectal-cancer/</guid>
		<description><![CDATA[ World J Gastroenterol . 2009 Dec 14; 15(46): 5879-81 Lu PH, Tao GQ, Shen W, Cai B, Jiang ZY, Sun J The occurrence of concomitant aortic aneurysm and colorectal cancer is a rare medical entity, and controversy surrounds its optimal treatment. We report a case of rectal cancer and concomitant aneurysm from the ascending aorta to the common iliac artery]]></description>
			<content:encoded><![CDATA[<p> World J Gastroenterol . 2009 Dec 14; 15(46): 5879-81 Lu PH, Tao GQ, Shen W, Cai B, Jiang ZY, Sun J The occurrence of concomitant aortic aneurysm and colorectal cancer is a rare medical entity, and controversy surrounds its optimal treatment. We report a case of rectal cancer and concomitant aneurysm from the ascending aorta to the common iliac artery</p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/surgery-for-rare-aneurysm-associated-with-colorectal-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Antioxidant properties of an endogenous thiol: Alpha-lipoic acid, useful in the prevention of cardiovascular diseases.</title>
		<link>http://www.betafootprint.com/medical-news/antioxidant-properties-of-an-endogenous-thiol-alpha-lipoic-acid-useful-in-the-prevention-of-cardiovascular-diseases/</link>
		<comments>http://www.betafootprint.com/medical-news/antioxidant-properties-of-an-endogenous-thiol-alpha-lipoic-acid-useful-in-the-prevention-of-cardiovascular-diseases/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:33 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[ala]]></category>
		<category><![CDATA[diet]]></category>
		<category><![CDATA[dietary]]></category>
		<category><![CDATA[dietary-intake]]></category>
		<category><![CDATA[heart-failure]]></category>
		<category><![CDATA[human-tissues]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[more-complete]]></category>
		<category><![CDATA[optimizing]]></category>
		<category><![CDATA[oxidized]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[racemic-mixture]]></category>
		<category><![CDATA[the-management]]></category>
		<category><![CDATA[the-prevention]]></category>
		<category><![CDATA[through-direct]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/antioxidant-properties-of-an-endogenous-thiol-alpha-lipoic-acid-useful-in-the-prevention-of-cardiovascular-diseases/</guid>
		<description><![CDATA[ J Cardiovasc Pharmacol . 2009 Nov; 54(5): 391-8 Ghibu S, Richard C, Vergely C, Zeller M, Cottin Y, Rochette L In the past few years, a growing interest has been given to the possible antioxidant functions of a natural acid, synthesized in human tissues: alpha-lipoic acid (ALA). Both the oxidized (disulfide) and reduced (dithiol: dihydrolipoic acid, DHLA) forms of ALA show antioxidant properties. ]]></description>
			<content:encoded><![CDATA[<p> J Cardiovasc Pharmacol . 2009 Nov; 54(5): 391-8 Ghibu S, Richard C, Vergely C, Zeller M, Cottin Y, Rochette L In the past few years, a growing interest has been given to the possible antioxidant functions of a natural acid, synthesized in human tissues: alpha-lipoic acid (ALA). Both the oxidized (disulfide) and reduced (dithiol: dihydrolipoic acid, DHLA) forms of ALA show antioxidant properties. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/antioxidant-properties-of-an-endogenous-thiol-alpha-lipoic-acid-useful-in-the-prevention-of-cardiovascular-diseases/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Orlistat: current status in clinical therapeutics.</title>
		<link>http://www.betafootprint.com/medical-news/orlistat-current-status-in-clinical-therapeutics/</link>
		<comments>http://www.betafootprint.com/medical-news/orlistat-current-status-in-clinical-therapeutics/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:32 +0000</pubDate>
		<dc:creator>Master</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[adverse-effect]]></category>
		<category><![CDATA[article]]></category>
		<category><![CDATA[define-the-role]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[expert-opin]]></category>
		<category><![CDATA[obesity-related]]></category>
		<category><![CDATA[provide-detail]]></category>
		<category><![CDATA[relatively-mild]]></category>
		<category><![CDATA[safety]]></category>
		<category><![CDATA[the-treatment]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[various-patient]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/orlistat-current-status-in-clinical-therapeutics/</guid>
		<description><![CDATA[ Expert Opin Drug Saf . ]]></description>
			<content:encoded><![CDATA[<p> Expert Opin Drug Saf . </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/orlistat-current-status-in-clinical-therapeutics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Octreotide LAR: safety and tolerability issues.</title>
		<link>http://www.betafootprint.com/medical-news/octreotide-lar-safety-and-tolerability-issues/</link>
		<comments>http://www.betafootprint.com/medical-news/octreotide-lar-safety-and-tolerability-issues/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:32 +0000</pubDate>
		<dc:creator>Master</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[been-performed]]></category>
		<category><![CDATA[compound]]></category>
		<category><![CDATA[cornerstone]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[expert-opin]]></category>
		<category><![CDATA[high-affinity]]></category>
		<category><![CDATA[incidental-case]]></category>
		<category><![CDATA[indications]]></category>
		<category><![CDATA[lower-incidence]]></category>
		<category><![CDATA[malfertheiner]]></category>
		<category><![CDATA[somatostatin]]></category>
		<category><![CDATA[the-cornerstone]]></category>
		<category><![CDATA[well-tolerated]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/octreotide-lar-safety-and-tolerability-issues/</guid>
		<description><![CDATA[ Expert Opin Drug Saf . 2009 Nov; 8(6): 755-68 Bornschein J, Drozdov I, Malfertheiner P BACKGROUND: Somatostatin analogues are the cornerstone in therapy of acromegaly and functioning neuroendocrine tumors]]></description>
			<content:encoded><![CDATA[<p> Expert Opin Drug Saf . 2009 Nov; 8(6): 755-68 Bornschein J, Drozdov I, Malfertheiner P BACKGROUND: Somatostatin analogues are the cornerstone in therapy of acromegaly and functioning neuroendocrine tumors</p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/octreotide-lar-safety-and-tolerability-issues/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A review of acitretin for the treatment of psoriasis.</title>
		<link>http://www.betafootprint.com/medical-news/a-review-of-acitretin-for-the-treatment-of-psoriasis/</link>
		<comments>http://www.betafootprint.com/medical-news/a-review-of-acitretin-for-the-treatment-of-psoriasis/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 10:20:31 +0000</pubDate>
		<dc:creator>Master</dc:creator>
				<category><![CDATA[medical news]]></category>
		<category><![CDATA[acitretin]]></category>
		<category><![CDATA[expert-opin]]></category>
		<category><![CDATA[generally-well]]></category>
		<category><![CDATA[literature]]></category>
		<category><![CDATA[safety]]></category>
		<category><![CDATA[since-the-last]]></category>
		<category><![CDATA[the-treatment]]></category>
		<category><![CDATA[the-treatments]]></category>
		<category><![CDATA[topical-therapy]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[updated-review]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/a-review-of-acitretin-for-the-treatment-of-psoriasis/</guid>
		<description><![CDATA[ Expert Opin Drug Saf . 2009 Nov; 8(6): 769-79 Lee CS, Li K BACKGROUND: Acitretin is an oral retinoid that is approved for the treatment of psoriasis]]></description>
			<content:encoded><![CDATA[<p> Expert Opin Drug Saf . 2009 Nov; 8(6): 769-79 Lee CS, Li K BACKGROUND: Acitretin is an oral retinoid that is approved for the treatment of psoriasis</p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/medical-news/a-review-of-acitretin-for-the-treatment-of-psoriasis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Sleep On Many Americans&#8217; Holiday Wish List</title>
		<link>http://www.betafootprint.com/uncategorized/more-sleep-on-many-americans-holiday-wish-list/</link>
		<comments>http://www.betafootprint.com/uncategorized/more-sleep-on-many-americans-holiday-wish-list/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 07:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[holiday]]></category>
		<category><![CDATA[holiday-slumber]]></category>
		<category><![CDATA[impact]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[season]]></category>
		<category><![CDATA[sleep]]></category>
		<category><![CDATA[sleepbetter]]></category>
		<category><![CDATA[sugar-plums]]></category>
		<category><![CDATA[survey]]></category>
		<category><![CDATA[the-holidays]]></category>
		<category><![CDATA[their-heads]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/more-sleep-on-many-americans-holiday-wish-list/</guid>
		<description><![CDATA[The kids may be sleeping soundly this season with "visions of sugar plums in their heads," but almost half of the nation's moms and dads (44%) say they are worried about being able to afford the holidays this year, with one in six Americans (17%) expecting to lose sleep due to holiday-induced stress. The findings are part of a national year-end survey - the SleepBetter.org Holiday Slumber Index, which measures the impact of the holidays on Americans' sleep patterns. ]]></description>
			<content:encoded><![CDATA[<p>The kids may be sleeping soundly this season with &#8220;visions of sugar plums in their heads,&#8221; but almost half of the nation&#8217;s moms and dads (44%) say they are worried about being able to afford the holidays this year, with one in six Americans (17%) expecting to lose sleep due to holiday-induced stress. The findings are part of a national year-end survey &#8211; the SleepBetter.org Holiday Slumber Index, which measures the impact of the holidays on Americans&#8217; sleep patterns. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/uncategorized/more-sleep-on-many-americans-holiday-wish-list/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tripep Receives Approval For Expanding The ChronVac-C(R) Study With One More Vaccination</title>
		<link>http://www.betafootprint.com/uncategorized/tripep-receives-approval-for-expanding-the-chronvac-cr-study-with-one-more-vaccination/</link>
		<comments>http://www.betafootprint.com/uncategorized/tripep-receives-approval-for-expanding-the-chronvac-cr-study-with-one-more-vaccination/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 05:00:00 +0000</pubDate>
		<dc:creator>Master</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[chron]]></category>
		<category><![CDATA[given-at-three]]></category>
		<category><![CDATA[highest]]></category>
		<category><![CDATA[highest-dose]]></category>
		<category><![CDATA[immune system / vaccines]]></category>
		<category><![CDATA[products-agency]]></category>
		<category><![CDATA[received-four]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[therapeutic]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/tripep-receives-approval-for-expanding-the-chronvac-cr-study-with-one-more-vaccination/</guid>
		<description><![CDATA[Tripep (STO:TPEP) received the approval from the Swedish Medical Products Agency and the local ethical committee to give three patients in the highest dose group in the ChronVac-C® study one additional treatment with the therapeutic vaccine. All twelve patients in the study have earlier received four treatments with ChronVac-C® given at three different doses and one month apart]]></description>
			<content:encoded><![CDATA[<p>Tripep (STO:TPEP) received the approval from the Swedish Medical Products Agency and the local ethical committee to give three patients in the highest dose group in the ChronVac-C® study one additional treatment with the therapeutic vaccine. All twelve patients in the study have earlier received four treatments with ChronVac-C® given at three different doses and one month apart</p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/uncategorized/tripep-receives-approval-for-expanding-the-chronvac-cr-study-with-one-more-vaccination/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Neurologix Completes All Surgical Procedures In Its Clinical Trial For Parkinson&#8217;s Disease</title>
		<link>http://www.betafootprint.com/uncategorized/neurologix-completes-all-surgical-procedures-in-its-clinical-trial-for-parkinsons-disease/</link>
		<comments>http://www.betafootprint.com/uncategorized/neurologix-completes-all-surgical-procedures-in-its-clinical-trial-for-parkinsons-disease/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 04:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[all-planned]]></category>
		<category><![CDATA[brain]]></category>
		<category><![CDATA[central-nervous]]></category>
		<category><![CDATA[clinical-trial]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[gene-transfer]]></category>
		<category><![CDATA[phase]]></category>
		<category><![CDATA[the-development]]></category>
		<category><![CDATA[the-treatment]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/neurologix-completes-all-surgical-procedures-in-its-clinical-trial-for-parkinsons-disease/</guid>
		<description><![CDATA[Neurologix, Inc. ]]></description>
			<content:encoded><![CDATA[<p>Neurologix, Inc. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/uncategorized/neurologix-completes-all-surgical-procedures-in-its-clinical-trial-for-parkinsons-disease/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hyperion Therapeutics Enrolls First Patient In Phase II Hepatic Encephalopathy Trial</title>
		<link>http://www.betafootprint.com/uncategorized/hyperion-therapeutics-enrolls-first-patient-in-phase-ii-hepatic-encephalopathy-trial/</link>
		<comments>http://www.betafootprint.com/uncategorized/hyperion-therapeutics-enrolls-first-patient-in-phase-ii-hepatic-encephalopathy-trial/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 03:00:00 +0000</pubDate>
		<dc:creator>Master</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[140-patients]]></category>
		<category><![CDATA[been-enrolled]]></category>
		<category><![CDATA[clinical-trial]]></category>
		<category><![CDATA[during-the-four]]></category>
		<category><![CDATA[episode-during]]></category>
		<category><![CDATA[neurology / neuroscience]]></category>
		<category><![CDATA[open-label]]></category>
		<category><![CDATA[proportion]]></category>
		<category><![CDATA[study-consists]]></category>
		<category><![CDATA[the-four-month]]></category>
		<category><![CDATA[the-proportion]]></category>
		<category><![CDATA[therapeutics]]></category>
		<category><![CDATA[will-enroll]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/hyperion-therapeutics-enrolls-first-patient-in-phase-ii-hepatic-encephalopathy-trial/</guid>
		<description><![CDATA[Hyperion Therapeutics, Inc. announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The multi-center study consists of an open label safety component followed by a randomized, double-blind, placebo-controlled study that will enroll approximately 140 patients with episodic hepatic encephalopathy in the US and Eastern Europe. ]]></description>
			<content:encoded><![CDATA[<p>Hyperion Therapeutics, Inc. announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The multi-center study consists of an open label safety component followed by a randomized, double-blind, placebo-controlled study that will enroll approximately 140 patients with episodic hepatic encephalopathy in the US and Eastern Europe. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/uncategorized/hyperion-therapeutics-enrolls-first-patient-in-phase-ii-hepatic-encephalopathy-trial/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New HealthMedia(R) Digital Coaching™ Programs Address Heart Disease Risk Factors And Help Reduce Health Care Costs</title>
		<link>http://www.betafootprint.com/uncategorized/new-healthmediar-digital-coaching%e2%84%a2-programs-address-heart-disease-risk-factors-and-help-reduce-health-care-costs/</link>
		<comments>http://www.betafootprint.com/uncategorized/new-healthmediar-digital-coaching%e2%84%a2-programs-address-heart-disease-risk-factors-and-help-reduce-health-care-costs/#comments</comments>
		<pubDate>Fri, 11 Dec 2009 02:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[behavior-change]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digital-coaching]]></category>
		<category><![CDATA[disease-risk]]></category>
		<category><![CDATA[health]]></category>
		<category><![CDATA[heart disease]]></category>
		<category><![CDATA[help-lower]]></category>
		<category><![CDATA[introduced-two]]></category>
		<category><![CDATA[johnson]]></category>
		<category><![CDATA[live-health]]></category>
		<category><![CDATA[only-the-web]]></category>
		<category><![CDATA[yxy]]></category>

		<guid isPermaLink="false">http://www.the-health-book.com/uncategorized/new-healthmediar-digital-coaching%e2%84%a2-programs-address-heart-disease-risk-factors-and-help-reduce-health-care-costs/</guid>
		<description><![CDATA[HealthMedia, Inc., a Johnson &#038; Johnson company, introduced two new Digital Coaching™ programs that help lower cardiovascular disease risk for employee populations. HealthMedia® ACHIEVE™ and HealthMedia® CONTROL™ improve cholesterol and blood pressure self-management through comprehensive and scalable Digital Coaching™ that focuses on behavior change and personal motivation. ]]></description>
			<content:encoded><![CDATA[<p>HealthMedia, Inc., a Johnson &#038; Johnson company, introduced two new Digital Coaching™ programs that help lower cardiovascular disease risk for employee populations. HealthMedia® ACHIEVE™ and HealthMedia® CONTROL™ improve cholesterol and blood pressure self-management through comprehensive and scalable Digital Coaching™ that focuses on behavior change and personal motivation. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.betafootprint.com/uncategorized/new-healthmediar-digital-coaching%e2%84%a2-programs-address-heart-disease-risk-factors-and-help-reduce-health-care-costs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
